- CureVac, a German biotech backed by Expense Gates, said Thursday it remains in talks with the EU to supply 225 million dosages of its prospective coronavirus vaccine.
- Shares of CureVac leapt more than 18%in premarket trading on Thursday.
- If an arrangement is reached, it would mark the company’s very first bilateral supply offer, according to Reuters
- View CureVac trade reside on Markets Insider
- Find Out More on Company Insider
Shares of CureVac, a German biotech company backed by Expense Gates, rose as much as 18%in premarket trading Thursday after the company said it is in talks with the European Commission to provide doses of its possible coronavirus vaccine.
The potential agreement with the European Commission intends to provide European Union member specifies with as much as 225 million dosages of the coronavirus vaccine, once it has been shown safe and efficient against COVID-19, the company said in a press release
The agreement would likewise provide the European Commission the alternative to acquire an additional 180 million doses, bringing the overall to 405 million doses of the possible vaccine.
If an arrangement is reached, it would mark the company’s very first bilateral supply deal, according to Reuters.
CureVac’s mRNA-based COVID-19 vaccine candidate is currently in a Stage 1 scientific trial at various sites in Germany and Belgium, intending to determine security and efficacy of the drug in people, the business said. It anticipates to have outcomes from the trial early in the 4th quarter of 2020, and move to the next phase not long after.